Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

tocilizumab

(toh-sih-LIH-zoo-mab)
A drug used to treat adults and children aged 2 years and older with severe or life-threatening cytokine release syndrome caused by a type of immunotherapy called chimeric antigen receptor (CAR) T-cell therapy. Tocilizumab is also used to treat certain types of arthritis and a condition that causes inflammation of the lining of the arteries. It is also being studied in the treatment of other conditions. Tocilizumab binds to receptors for a protein called interleukin-6 (IL-6), which is made by white blood cells and other cells in the body. This may help lower the body’s immune response and reduce inflammation. Tocilizumab is a type of monoclonal antibody. Also called Actemra.
Search NCI's Dictionary of Cancer Terms